{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T05:47:12Z","timestamp":1671083232069},"reference-count":41,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,7,1]]},"DOI":"10.2169\/internalmedicine.6728-20","type":"journal-article","created":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T22:06:11Z","timestamp":1612130771000},"page":"2061-2066","source":"Crossref","is-referenced-by-count":1,"title":["Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir"],"prefix":"10.2169","volume":"60","author":[{"given":"Mai","family":"Totsuka","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Honda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Yamana","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kumagawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Masuzaki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shini","family":"Kanezawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Nirei","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiko","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol 54: 367-376, 2019.","DOI":"10.1007\/s00535-018-1532-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kanda T, Lau GKK, Wei L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int 13: 649-661, 2019.","DOI":"10.1007\/s12072-019-09988-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Reddy KR, Pol S, Thuluvath PJ, et al. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int 38: 821-833, 2018.","DOI":"10.1111\/liv.13596"},{"key":"4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","volume":"42","author":"P Simmonds","year":"2005","unstructured":"4. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973, 2005.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Murphy DG, Sablon E, Chamberland J, et al. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol 53: 967-972, 2015.","DOI":"10.1128\/JCM.02831-14"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Borgia SM, Hedskog C, Parhy B, et al. Identification of a novel hepatitis C Virus genotype from punjab, india: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis 218: 1722-1729, 2018.","DOI":"10.1093\/infdis\/jiy401"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Omata M, Kanda T, Yokosuka O, et al. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int 9: 486-507, 2015.","DOI":"10.1007\/s12072-015-9630-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hayashi K, Fukuda Y, Nakano I, et al. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatol Res 25: 409-414, 2003.","DOI":"10.1016\/S1386-6346(03)00016-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. J Viral Hepat 21: 762-768, 2014.","DOI":"10.1111\/jvh.12312"},{"key":"10","unstructured":"10. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15: 645-653, 2015."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol 54: 87-95, 2019.","DOI":"10.1007\/s00535-018-1503-x"},{"key":"12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"12. Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 67: 505-513, 2018.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol 53: 557-565, 2018.","DOI":"10.1007\/s00535-017-1391-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53: 566-575, 2018.","DOI":"10.1007\/s00535-017-1396-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II\/III study. J Gastroenterol 52: 520-533, 2017.","DOI":"10.1007\/s00535-016-1285-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kanda T, Matsuoka S, Moriyama M. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt. Hepatol Int 12: 291-293, 2018.","DOI":"10.1007\/s12072-018-9883-9"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Aikawa T, Tsuda F, Ueno C, et al. Comparison of test results of serogrouping and core region PCR-based genotyping in patients with chronic hepatitis C virus infection: analysis of inderminate or discrepant cases and identification of a 2b\/1b recombinant HCV. Kanzo 57: 447-456, 2016 (in Japanese, Abstract in English).","DOI":"10.2957\/kanzo.57.447"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Guerra J, Garenne M, Mohamed MK, et al. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 19: 560-567, 2012.","DOI":"10.1111\/j.1365-2893.2011.01576.x"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362, 1989.","DOI":"10.1126\/science.2523562"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244: 362-364, 1989.","DOI":"10.1126\/science.2496467"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17: 1062-1068, 2017.","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"22","unstructured":"22. Aghemo A, Alberti A, Andreone P, et al. Effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis S1590-8658: 30401-1."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zuckerman E, Gutierrez JA, Dylla DE, et al. Eight weeks of treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment-na\u00efve patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 18: 2544-2553.e6, 2020.","DOI":"10.1016\/j.cgh.2020.06.044"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Flamm SL, Kort J, Marx SE, et al. Effectiveness of 8-week glecaprevir\/pibrentasvir for treatment-na\u00efve, compensated cirrhotic patients with chronic hepatitis C infection. Adv Ther 37: 2267-2274, 2020.","DOI":"10.1007\/s12325-020-01301-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol 72: 441-449, 2020.","DOI":"10.1016\/j.jhep.2019.10.020"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Brown A, Welzel TM, Conway B, et al. Adherence to pan-genotypic glecaprevir\/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials. Liver Int 40: 778-786, 2020.","DOI":"10.1111\/liv.14266"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: Part 1 of the DORA Study. Hepatology 71: 456-462, 2020.","DOI":"10.1002\/hep.30840"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Berg T, Naumann U, Stoehr A, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 49: 1052-1059, 2019.","DOI":"10.1111\/apt.15222"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Grebely J, Dore GJ, Alami NN, et al. Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy 66: 73-79, 2019.","DOI":"10.1016\/j.drugpo.2019.01.011"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Foster GR, Asselah T, Kopecky-Bromberg S, et al. Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One 14: e0208506, 2019.","DOI":"10.1371\/journal.pone.0208506"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. D'Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol 70: 379-387, 2019.","DOI":"10.1016\/j.jhep.2018.11.011"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Krishnan P, Pilot-Matias T, Schnell G, et al. Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials. Antimicrob Agents Chemother 62: e01249-18, 2018.","DOI":"10.1128\/AAC.01249-18"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Shiha G, Soliman R, ElBasiony M, et al. Sofosbuvir plus daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatol Int 12: 339-347, 2018.","DOI":"10.1007\/s12072-018-9861-2"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Abd-Elsalam S, Sharaf-Eldin M, Soliman S, et al. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol 163: 51-56, 2018.","DOI":"10.1007\/s00705-017-3573-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ahmed H, Abushouk AI, Attia A, et al. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: a systematic review and meta-analysis. J Infect Public Health 11: 156-164, 2018.","DOI":"10.1016\/j.jiph.2017.09.004"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Flamm S, Mutimer D, Asatryan A, et al. Glecaprevir\/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2\/3 analysis. J Viral Hepat 26: 337-349, 2019.","DOI":"10.1111\/jvh.13038"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Sugiura A, Joshita S, Umemura T, et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat 25: 1462-1471, 2018.","DOI":"10.1111\/jvh.12973"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mawatari S, Oda K, Kumagai K, et al. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. Hepatol Res 50: 453-465, 2020.","DOI":"10.1111\/hepr.13474"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Sano T, Akuta N, Suzuki F, et al. Role of NS5A-L31\/Y93 double wild-type in failure of glecaprevir\/pibrentasvir double therapy in two patients with a history of direct-acting antiviral agent failure: an ultra-deep sequencing analysis. Intern Med 58: 2657-2662, 2019.","DOI":"10.2169\/internalmedicine.2604-18"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Merli M, Rossotti R, Travi G, et al. Sustained virological response with 16-week glecaprevir\/pibrentasvir after failure to sofosbuvir\/velpatasvir in post-transplant severe HCV recurrence in HIV. Transpl Infect Dis 21: e13165, 2019.","DOI":"10.1111\/tid.13165"},{"key":"41","unstructured":"41. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis [Internet]. [cited 2020 Dec 3]. Available from: https:\/\/www.hcvguidelines.org\/treatment-naive\/simplified-treatment-compensated-cirrhosis"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/13\/60_6728-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T03:40:57Z","timestamp":1670989257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/13\/60_6728-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":41,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6728-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"article-number":"6728-20"}}